Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Jun;16(6):897-901.
doi: 10.1016/j.jtho.2021.03.003. Epub 2021 Mar 23.

The International Association for the Study of Lung Cancer Molecular Database Project: Objectives, Challenges, and Opportunities

Raymond U Osarogiagbon  1 , Ramon Rami-Porta  2 , Ming Sound Tsao  3 , Luis M Montuenga  4 , Katherine K Nishimura  5 , Dorothy J Giroux  5 , William Travis  6 , Hisao Asamura  7 , Valerie Rusch  8 , David P Carbone  9 , Fred R Hirsch  10
Affiliations
Editorial

The International Association for the Study of Lung Cancer Molecular Database Project: Objectives, Challenges, and Opportunities

Raymond U Osarogiagbon et al. J Thorac Oncol. 2021 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest:

Dr. Osarogiagbon owns patents for a lymph node specimen collection kit; stocks in Eli Lilly, Gilead Sciences, and Pfizer; has worked as a paid research consultant for the American Cancer Society, the Association of Community Cancer Centers, Astra Zeneca, Eli Lilly, Triptych Healthcare Partners, and Genentech/Roche; and is founder of Oncobox Device, Inc.

Dr. Luis M. Montuenga; Astra-Zeneca: Speaker’bureau and Research Grant. AMADIX: Licensed patent co-holder on Complement in Lung Cancer early detection. BMS: Research Grant

Dorothy J. Giroux; Reports grants from IASLC during the conduct of the study.

Dr. Hisao Asamura; Reports grants from Grant, grants from Grant, grants from Grant, grants from Grant, grants from Grant, personal fees from lecture fee, personal fees from lecture fee, outside the submitted work.

Dr. Valerie Rusch; Reports grants from Genelux, Inc., grants from Genentech, non-financial support from Intuitive Surgical, other from NIH Coordinating Center for Clinical Trials, other from MARS 2 Trial Data Safety Monitoring Committee, outside the submitted work.

Dr. Fred R. Hirsch; Participated in scientific advisory boards for: BMS, Merck, AstraZeneca, Novartis, Daiichi, Regeneron/Sanofi, OncoCyte, Amgen, Genentech/Roche. Research funding (through University of Colorado) from Amgen, Biodesix, Rain Therapeutics, Mersana, Abbvie. Patents (through University of Colorado): ‘EGFR protein and Gene Copy Number as Predictive Biomarkers for EGFR Therapy”.

References

    1. Global Burden of Disease Cancer Collaboration. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2019;5:1749–1768. Erratum in: JAMA Oncol. 2020;6:444. Erratum in: JAMA Oncol. 2020;6:789. - PMC - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30. - PubMed
    1. Pao W, Hutchinson KE. Chipping away at the lung cancer genome. Nat Med. 2012;18:349–51. - PubMed
    1. Howlader N, Forjaz G, Mooradian MJ, et al. The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med. 2020;383:640–649. - PMC - PubMed
    1. Adjei AA. Controversies in Thoracic Oncology. J Thorac Oncol. 2021;16:366–367. - PubMed

Publication types